In November 2021, the FDA approved semaglutide specifically for chronic weight management at higher doses under the brand name Wegovy, formally recognizing weight loss as a primary therapeutic indication
If you miss three or more consecutive days, you may experience mild nausea when resuming due to reduced tolerance
Weight loss medications like glucagon-like peptide-1 receptor agonists, or GLP-1s which include Wegovy (pill and pen), Zepbound , Foundayo , and Saxenda have gotten a lot of attention recently for their ability to help people lose significant amounts of weight and keep it off
Worked great
Its approval for obesity treatment has broadened its market appeal, especially as global obesity rates rise
For comparative context, researchers may reference Semaglutide, a selective GLP-1 receptor agonist, and Tirzepatide, a dual GIP/GLP-1 receptor agonist, when examining how incremental receptor targeting across this compound class affects metabolic pathway outcomes